Every month: The result of premenstrual dysphoric disorders
Department of Nursing, Wagner College, Staten Island, New York, USA.
Review
International Journal of Scientific Research Updates, 2022, 04(01), 210–214.
Article DOI: 10.53430/ijsru.2022.4.1.0127
Publication history:
Received on 26 July 2022; revised on 30 August 2022; accepted on 01 September 2022
Abstract:
Methods: Research was conducted using self-experience along with scientific literature findings to fully understand the physical and emotional syndromes of premenstrual dysphoric disorders (PMDD).
Findings: Correlation with low progesterone in relation to negative affective and physical symptoms during the follicle and luteal phase were observed. Allopregnanolone, a neurosteroid, as a therapeutic agent can alleviate PMDD symptoms. Specific nutritional sources can also help alleviating the presenting symptoms.
Conclusion: Awareness about PMDD symptoms is warranted in women experiencing them. Providers need to be familiar of the emotional and physical effect of low progesterone and the mechanism of action of Allopregnanolone in treating PMDD, when other interventions such as psychotherapy and other pharmacological intervention failed.
Keywords:
Premenstrual Dysphoric Disorder; Low Progesterone; Allopregnanolone; Neurosteroid; Follicle phase and Luteal phase
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0